Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04140695 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
NCT04140695: Clinical Trial Phase 3 study, sponsored by Vanda Pharmaceuticals.
NCT04140695 is a Phase 3 study that was terminated before completion, run by Vanda Pharmaceuticals. The registered enrollment target is 87 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04140695, a Phase 3 study, was terminated before completion, sponsored by Vanda Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
Primary Outcome
The WI-NRS responder is defined as a patient achieving at least 4 points reduction from baseline in weekly average of diary WI-NRS. Responses were measured on a scale of 0 - 10, with 0 being "no itch" and 10 being the "worst itch imaginable".
Interventions
- DRUG Placebo
- DRUG Tradipitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2020-10-14 |
| Phase | Phase 3 |
Why NCT04140695 stopped before completion
NCT04140695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04140695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04140695 about?
NCT04140695 is a clinical study titled "Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)". This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
What is the current status of trial NCT04140695?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2019-10-21. Estimated completion is 2020-10-14.
What interventions are being tested in trial NCT04140695?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG).
Who is sponsoring clinical trial NCT04140695?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04140695's enrollment target sits among peer trials
87 1742nd of 2000 higher than 256 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI